Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 7, 2014; 20(29): 9732-9743
Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.9732
Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.9732
Biomarker | Incidence | Prognostic value | Predictive value |
B-RAF mutations | 4%-15% | Poor prognosis[38,49,62,64,66,68,72,74,83] | Controversial data |
K-RAS mutations | 40% | Controversial data[36,65,68,72,86] | Major predictor of resistance to anti-EGFR mAbs[24,37,39,56,61] |
Mut G13D | 15%-20% | Weaker resistance[52] | |
N-RAS mutations | 3%-5% | Predictor of resistance[59,69] | |
PI3KCA mutations | 10%-20% | Conflicting results[28,30,61,65,70,71,73] | Controversial data[61,70,71,73] |
PTEN status | 20%-40% | Conflicting results[31,32,35,81,87] | Controversial data[31,70] |
- Citation: De Stefano A, Carlomagno C. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9732-9743
- URL: https://www.wjgnet.com/1007-9327/full/v20/i29/9732.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i29.9732